{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:22:13Z","timestamp":1788434533419,"version":"build-2803163510"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"unspecified","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,10]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumour necrosis factor \u03b1 (TNFi) and interleukin 17 (IL-17) inhibitors have demonstrated efficacy and safety in psoriatic arthritis (PsA) therapy through head-to-head randomised controlled trials, but evidence from real-world clinical practice (RWE) remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adalimumab vs Ixekizumab Real-world Effectiveness is a multicentre cohort study, aimed at comparing the effectiveness of these drugs in a \u2018real-world\u2019 PsA population. The primary outcome consisted of mixed-effects models comparing Disease Activity in Psoriatic Arthritis (DAPSA) and Psoriasis Areas and Severity Index (PASI) over 12 months in both treatment groups. Remission outcomes (DAPSA; Minimal Disease Activity (MDA)) were analysed using time-dependent Cox models adjusted for confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 437 patients (42% on adalimumab (ADA); 57% on ixekizumab (IXE)) were enrolled. At baseline, the ADA group mainly showed axial and nail involvement, while the IXE group was mostly biologic disease-modifying antirheumatic drug (bDMARD)-experienced and had higher C reactive protein levels and worse functional status.<\/jats:p>\n                    <jats:p>The DAPSA score improved in both groups, and between-treatment differences in DAPSA pathways over time were not significant. Probabilities of achieving DAPSA remission or MDA did not differ by drug at 12 months. PASI improved similarly in both groups, but IXE showed a greater early reduction from baseline at 3\u2009months. DAPSA remission and MDA were primarily associated with male sex, absence of nail psoriasis, higher PASI, fewer prior bDMARDs and better functional status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This RWE study showed that ADA and IXE provide similar 12-month joint outcomes, while IXE showed a faster skin response. Baseline demographic and clinical features affect the chance of remission, highlighting the importance of personalised treat-to-target approaches in PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006667","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:34:41Z","timestamp":1774366481000},"page":"e006667","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the \u2018AIRE\u2019 multicentre study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-8460","authenticated-orcid":false,"given":"Valentino","family":"Paci","sequence":"first","affiliation":[{"name":"Clinica Medica, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-464X","authenticated-orcid":false,"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[{"name":"Rheumatology Institute, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fontanarosa","sequence":"additional","affiliation":[{"name":"Centre of Epidemiology, Biostatistics and Medical Informatics, Marche Polytechnic University, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Celletti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Science of Aging, Medical Clinic, SS. Annunziata Hospital of Chieti, Gabriele d\u2019Annunzio University of Chieti and Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Foti","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raissa","family":"Di Zio","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-5205","authenticated-orcid":false,"given":"Fabio Massimo","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Rheumatology and Internal Medicine Department, Molise University, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Di Penta","sequence":"additional","affiliation":[{"name":"Department of Medicine and Science of Aging, Medical Clinic, SS. Annunziata Hospital of Chieti, Gabriele d\u2019Annunzio University of Chieti and Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Visalli","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Agostinelli","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marchionni","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Department of Medicine-DIMED, Rheumatology Unit, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-6439","authenticated-orcid":false,"given":"Luca","family":"Quartuccio","sequence":"additional","affiliation":[{"name":"Rheumatology Institute, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Gesuita","sequence":"additional","affiliation":[{"name":"Centre of Epidemiology, Biostatistics and Medical Informatics, Marche Polytechnic University, Ancona, Italy"},{"name":"IRCCS INRCA, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Moroncini","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Maria","family":"Luchetti Gentiloni","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[{"name":"Rheumatology and Internal Medicine Department, Molise University, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026090304053446000_12.1.e006667.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026090304053446000_12.1.e006667.2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","article-title":"Impact of psoriatic disease on quality of life: interim results of a global survey","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026090304053446000_12.1.e006667.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04775-2"},{"key":"2026090304053446000_12.1.e006667.4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1389201021666200928095521","article-title":"Novel therapeutic approaches and treatment targets for psoriatic arthritis","volume":"22","author":"Benfaremo","year":"2021","journal-title":"Curr Pharm Biotechnol"},{"key":"2026090304053446000_12.1.e006667.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120251"},{"key":"2026090304053446000_12.1.e006667.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2026090304053446000_12.1.e006667.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2026090304053446000_12.1.e006667.8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026090304053446000_12.1.e006667.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"2026090304053446000_12.1.e006667.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2026090304053446000_12.1.e006667.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2026090304053446000_12.1.e006667.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"2026090304053446000_12.1.e006667.13","doi-asserted-by":"crossref","unstructured":"Celletti E , Gualdi G , Sabatini E , et al . Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review. Reumatismo 2025;77. doi:10.4081\/reumatismo.2025.1694","DOI":"10.4081\/reumatismo.2025.1694"},{"key":"2026090304053446000_12.1.e006667.14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03236-y"},{"key":"2026090304053446000_12.1.e006667.15","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1007\/s12325-025-03258-9","article-title":"Real-world evidence for ixekizumab in the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: systematic literature review 2022\u20132023","volume":"42","author":"Puig","year":"2025","journal-title":"Adv Ther"},{"key":"2026090304053446000_12.1.e006667.16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40744-025-00784-4","article-title":"Real-world effectiveness of bimekizumab in predominantly difficult-to-treat patients with psoriatic arthritis followed in a combined dermatology\u2013rheumatology clinic: a 24-week multicenter study","volume":"12","author":"Zabotti","year":"2025","journal-title":"Rheumatol Ther"},{"key":"2026090304053446000_12.1.e006667.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2026090304053446000_12.1.e006667.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5338"},{"key":"2026090304053446000_12.1.e006667.19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2083"},{"key":"2026090304053446000_12.1.e006667.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102915","article-title":"Real-world data: bridging the gap between clinical trials and practice","volume":"78","author":"Wilson","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026090304053446000_12.1.e006667.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2026090304053446000_12.1.e006667.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2026090304053446000_12.1.e006667.23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","article-title":"Psoriatic arthritis in males and females: differences and similarities","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026090304053446000_12.1.e006667.24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40744-024-00678-x","article-title":"Gender differences in perceptions of psoriatic arthritis disease impact, management, and physician interactions: results from a global patient survey","volume":"11","author":"Eder","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026090304053446000_12.1.e006667.25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002457","article-title":"Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis","volume":"8","author":"Coates","year":"2022","journal-title":"RMD Open"},{"key":"2026090304053446000_12.1.e006667.26","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.1202a104","article-title":"Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial","volume":"12","author":"Reich","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"2026090304053446000_12.1.e006667.27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-021-00388-8","article-title":"Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-na\u00efve psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H","volume":"9","author":"Kristensen","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026090304053446000_12.1.e006667.28","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/rheumatology\/keae060","article-title":"Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis","volume":"63","author":"McGonagle","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026090304053446000_12.1.e006667.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30564-X"},{"key":"2026090304053446000_12.1.e006667.30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/mr\/road111","article-title":"Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis","volume":"34","author":"Takami","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026090304053446000_12.1.e006667.31","doi-asserted-by":"crossref","first-page":"151988","DOI":"10.1016\/j.semarthrit.2022.151988","article-title":"Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies","volume":"55","author":"Lalor","year":"2022","journal-title":"Semin Arthritis Rheum"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:05:44Z","timestamp":1788433544000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,24]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006667"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006667","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}